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The c-myc proto-oncogene linked to the mouse Thy-1 gene transcriptional unit predisposes
mice to development of thymic tumors consisting predominantly of immature CD4 CD8
cells. In an attempt to immortalize immature T cells expressing a known T-cell antigen
receptor (TCR), Thy-1/c-myc transgenic mice were bred to TCR transgenic mice (F5),
and CD4 CD8 cell lines were established from thymic tumors in double-transgenic mice.
These cells expressed high-level heat-stable antigen (HSA) and were able to undergo
programmed cell death upon induction with steroids and CD3 cross-linking, but not with
cognate peptide. In addition, one line had rearranged and transcribed endogenous TCR c
and genes, in spite of the fact that transgenic c and genes were also expressed.
Furthermore, we show that Thy-1/myc transgenic mice deficient in recombination activat-
ing gene-1 (RAG-l) do not develop tumors, in contrast to RAG-1-/- mice, which are also
transgenic for both Thy-1/myc and the F5 TCR. This indicates that in order for thymocytes
to be transformed by the Thy-myc transgene, they need to proceed to the double-positive
stage.
KEYWORDS: Immature thymocytes, F5/Thy-l-myc transgenic mice, programmed cell death, TCR gene rearrangement, RAG-1 genes.
INTRODUCTION
Overexpression of the c-myc proto-oncogene in
humans has been implicated in the development of
T- and B-cell leukemia, in which chromosomal
translocations bring the c-myc in close proximity
to either TCR- or immunoglobulin-gene regulatory
elements (for reviews, see Dalla-Favera et al., 1982;
Casares et al., 1993; Gauwerky and Croce, 1993;
Stephenson et al., 1993). In an attempt to establish
immature thymocyte lines, we previously generated
a transgenic mouse model carrying the murine
c-myc under the control of regulatory sequences of
T-cell-specific Thy-1 gene. Several lines of Thy-1/
c-myc (TM) transgenic mice developed thymic tu-
mors from which cell lines of both nonadherent
(thymocytes) and adherent (epithelial cells) pheno-
types were established (Spanopoulou et al., 1989).
All established thymocyte lines from these mice
were CD4 CD8 double-positive and expressed
high levels of transgenic c-myc. Analysis of TCR-
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gene rearrangements in the thymic tumors revealed
that thymocytes were of oligoclonal origin, suggest-
ing that oncogenic transformation occurred at the
CD4 CD8 stage in a stochastic manner. Those
data supported the hypothesis that tumorigenesis is
a multistep process and cooperation of c-myc with
other genetic mutation(s) is required for neoplastic
transformation, as had also been shown by others
(Adams and Cory, 1992). It was postulated at the
time that the secondary event necessary to cooper-
ate with the myc gene and transform the thymocytes
occurred at the double-positive (CD4 CD8 /) stage
of development.
An in vitro system of differentiation from double-
positive to CD4 single-positive stage has been de-
scribed for an immature thymocyte line (Kaye and
Ellenberger, 1992). In order to generate a system
that would generate CD8 single-positive cells from
immortalized immature thymocytes, we bred TM
mice with mice transgenic for an TCR (F5)
that recognizes a peptide from influenza virus
nucleoprotein in the context of H-2D
b (Mamalaki
et al., 1992). The F5/TM double-transgenic mice
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developed thymic tumors from which we were able
to derive immature CD4 CD8
/ cell lines. Here we
show that these double-positive (DP) cell lines are
functionally immature and undergo programmed
cell death upon induction with steroids and cross-
linking of CD3 by antibodies. In contrast, these cell
lines were refractory to treatment with antigenic
peptides, suggesting either that the levels of the
transgenic TCR are insufficient to mediate antigen-
specific signals or that the TCP is uncoupled from
CD3-1inked downstream signal-transduction ma-
chineries.
In order to avoid complications of endogenous
T-cell receptors interfering with selection events in
the thymus and affecting the transformation pro-
cesses F5/TM double-transgenic mice were bred
into a Recombination Activating Gene 1 (RAG-l)
deficient background (Spanopoulou et al., 1994).
F5/TM/RAG-1 -/- mice developed thymic tumors
from which cell lines were isolated that expressed
transiently the transgenic TCR. In contrast,
TM/RAG-1 -/- mice do not develop thymic tumors,
indicating that for transformation to take place,
thymocytes have to enter the double-positive
(CD4
/ 8 /) stage of development.
RESULTS
Development of Thymic Tumors in F5.TM25
Double-Transgenic Mice
It has previously been shown that different TM
mouse lines give rise to thymic tumors of various
phenotypes with respect to CD4, CD8, and HSA
expression (Spanopoulou et al., 1989; Y.T. unpub-
lished observation). Thus, in an attempt to obtain
thymic tumors and immortalized cell lines of imma-
ture phenotype, the TM25 line that produced HSA-
high cell lines at a high frequency was backcrossed
from (CBA x B10) F to B10 background until they
were H-2
bb and then to F5 TCR transgenic mice.
Double-transgenic mice (F5/TM25bb) developed
thymic tumors after similar latency periods to the
parental TM25 mice. Peripheral lymphadenopathy
was also observed in some F5/TM25 mice.
In order to determine the phenotype of cells
expanded in the thymic tumor, thymic tumor cells
were stained for CD4, CD8, and CD3,
V11(transgenic TCR), or HSA; lymphnode cells
were also stained with CD4 and CD8. Figure 1
shows analysis of lymphoid tissues from a
F5.TM25.1 mouse that developed a thymic tumor
but did not have peripheral metastasis. The thymic
tumor consisted largely of CD4+CD8 double-
positive (DP) cells (76.7%), but also contained
CD8
/ (5.2%) and CD4
/ (12.4%) single-positive
(SP) cells (Fig. l a). The number of SP cells in the
lymph node was similar to that of normal mice, but
there was a skewing toward CD8
/ cells due to
positive selection of the class MHC-restricted F5
TCR transgenic T cells (Fig. lb). Thymic tumor cells
in the F5.TM25.1 mouse expressed CD3 (Fig. lc,
solid line), and V11 (Fig. ld, solid line) at levels
comparable to those seen in the thymus of F5 mice
(broken line). Also, F5.TM25.1 thymocytes were
immature as judged by their high levels of HSA, as
shown in Fig. l e. These data suggest that immature
DP thymocytes expressing the transgenic TCR were
transformed in F5.TM25.1 mouse.
Establishment of Immature DP Cell Lines from
F5.TM25.1 Mouse
In an attempt to establish immature T-cell lines
expressing a known TCR, F5.TM25.1 thymic tumor
cells were cultured in vitro as described before
(Spanopoulou et al., 1989). Several cell lines and
clones were derived, all of which expressed high
levels of CD4 and CD8. Figure 2a illustrates expres-
sion of CD4 and CD8 on a representative clone
F5.TM25.1.2 (25.1.2)compared to F5 thymocytes.
Expression of TCR and HSA on 25.1.2 cells were
also assessed in comparison with adult F5 thymo-
cytes. As shown in Fig. 2b, 25.1.2 cells expressed
low to intermediate levels of CD3 as compared to
that of DP cells in F5 mice, considering the higher
auto-fluorescence (dashed line) of cultured 25.1.2
cells. In contrast, the level of V11 on 25.1.2 cells
was much lower than that on most F5 thymocytes
(Fig. 2c) or cells freshly isolated from the tumor.
Such a difference between levels of CD3 (low or
intermediate) and V11 (very low) suggested that
25.1.2 cells have different CD3/V11 stoichiometry
from that of F5 thymocytes, indicating that in the
cultured tumor cells, other receptors may be ex-
pressed competing with transgenic-receptor mole-
cules for CD3 complexes. Furthermore, higher levels
of HSA expression were observed on the line com-
pared to fresh tumor cells and this was taken as
indication that the 25.1.2 cells are immature (Fig.
2d).
In order to assess the expression of transgenic
and/or endogenous TCR genes in 25.1.2 cells, totalIMMATURE THYMOCYTE CELL LINES 281
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FIGURE 1. Phenotype of T cells in the thymus and periphery of F5.TM25.1 mouse. (a) Expression of CD4 and CD8 on thymic tumor
cells in F5.TM25.1 mouse compared with normal F5 mouse. (b) Expression of CD4 and CD8 on lymph-node cells in F5.TM25.1 mouse.
A large proportion of CD8 SP cells is characteristic of F5 transgenic mice. In this particular mouse, there was no metastasis of DP
thymic tumor cells observed in some other mice. Histograms showing levels of (c) CD3, (d) V11. and (e) HSA on thymic tumor cells
are shown by solid lines. Dotted lines and broken lines in each histogram represent the levels of these molecules on nontransgenic
and adult F5 thymocytes, respectively.282 M. MURDJEVA et al.
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FIGURE 2. Phenotype of F5.TM25.1.2 cell line. (a) Expression of CD4 and CD8 on 25.1.2 cells and F5 thymocytes. Histograms
illustrating expression of (b) CD3, (c) V11, and (d) HSA. Left panels and right panels represent 25.1.2 and control F5 thymocytes,
respectively. Dotted lines in histograms are of unstained controls.
RNA was extracted and reverse-transcribed to gen-
erate complementary DNA. For PCR amplification
of transgenic TCR chains, sense primers for V(z4 and
V11 were used in combination with antisense
primers for a part of the expression cassette (exon 2
of human CD2 gene located downstream of the
cDNA inserts) (Mamalaki et al., 1993). As shown in
Figure 3a, PCR products of predicted sizes were
detected for both transgenic (z and chains, provid-
ing evidence that 25.1.2 cells transcribe the F5 TCR
0 and transgenes. Next, in order to assess whether
endogenous (z and TCR genes were expressed by
these cells, panels of sense primers for different V0
andV segments were used with antisense primers
for 0 or constant regions.
Figure 3b shows the presence of PCR products
from V(z4 (transgenic) and V08 segments, demon-
strating that an endogenous TCR (z gene is rear-
ranged and transcribed in 25.1.2 cells. Furthermore,
25.1.2 cells express an endogenous TCR chainIMMATURE THYMOCYTE CELL LINES 283
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FIGURE 3. RNA-PCR analysis of TCR gene transcripts. (a)
Transgenic TCR products were detected using sense primers for
Vc4 and V11 in combination with antisense primers for a part
of the vector (hCD2) or the constant region of the chain, mRNA
from 25.1.2 cells was used, except for one sample in which the
mRNA was isolated from the parental 25.1 cell line and is
indicated by an asterisk (’). (b) Expression of rearranged endog-
enous TCR ( loci was examined using a panel of sense primers
for V(1-V12 gene segments with an antisense primer for C(. A
Vc4 specific band could be derived either from transgenic or
endogenous ( chains, whereas a product for V(8 could only
originate from endogenous c gene. (c) Rearrangement of endog-
enous TCR genes was assessed using a panel of V1-V12
family-specific sense primers and aC antisense primer. A band
for V11 could be due to mRNA from either the transgenic or an
endogenous gene. The one for V5 can only come from tran-
scription of an endogenous TCR gene. Markers used were
concatamers of 123-bp DNA fragments.
(V5) in addition to transgenic V11, as shown in
Fig. 3c. Although the presence of transcription
products from endogenous c and TCR genes does
not prove they are expressed as proteins on cell
surface, the finding that endogenous chains are also
expressed in these cells may explain the higher
stoichiometry of CD3 over V11.
F5.TM25.1.2 Cells Undergo Programmed Cell
Death
In order to examine if 25.1.2 retained characteristics
of immature DP thymocytes, 25.1.2 cells were
treated for 12 hr with 1 x 10-
6 M hydrocortisone,
a known steroid inducer of programmed cell death
in immature thymocytes (Wyllie, 1980). Total DNA
was extracted after treatment and was analyzed in
an agarose gel. As shown in Fig. 4a, the steroid-
induced programmed cell death (apoptosis) in 25.1.2
cells, produced a prominent ladder of fragmented
DNA.
F5 TCR-bearing immature double-positive thy-
mocytes respond in vivo or in vitro to cognate
peptide (influenza nucleoprotein 1968 (c366-374)
by undergoing apoptosis. Thus, we studied the
effects of cognate peptide on the F5.TM cell line.
25.1.2 cells were cultured with peritoneal macroph-
ages in the presence of various concentrations of the
peptide recognized by the F5 TCR (1968 NP). Figure
4b shows viable cell numbers relative to those seen
in cultures without peptide. It appeared that 25.1.2
cells were not affected by cognate peptide, whereas
F5 thymocytes were deleted at as low as 10-
9 M
concentration of the peptide as reported before
(Tanaka et al., 1993). CD4 or CD8 levels on 25.1.2
cells did not change after peptide treatment (data
not shown). These data are in contrast to the
previous observation of steroid-induced pro-
grammed cell death of 25.1.2 cells. Such a resistance
of 25.1.2 cells to peptide treatment could be either
due to insufficient level of TCR expression (already
lower than that observed on fresh tumor cells) or a
defect in TCR-linked signal-transduction pathways.
Thus, if 25.1.2 cells expressed endogenous TCR
and ( chains instead of transgenic F5 TCR, as
discussed before (Fig. 3), 25.1.2 cells might not
recognize the 1968 NP. Alternatively, if the low
levels of F5 TCR present on the 25.1.2 cells were
sufficient to confer antigen-specific response, there
could be uncoupling of the TCR and CD3 or its
downstream signal-transduction system in the cell.284 M. MURDJEVA et al.
In order to resolve this issue, 25.1.2 cells were
stimulated by direct cross-linking of CD3a with the
antibody 145-2Cll (Leo et al., 1987) through Fc
receptors on a macrophage cell line J774A.1. Cocul-
ture of 25.1.2 cells with J774A.1 cells alone did not
affect 25.1.2 cells (Figure 4c). In contrast, addition of
2Cll at 70 ng/ml or 10 g/ml concentration caused
reduction in numbers of viable 25.1.2 cells, which
was associated with DNA fragmentation, as shown
in Fig. 4d. These data demonstrate that the 25.1.2
cell line has an intact CD3-1inked signal-
transduction mechanism, and that the most likely
reason for their nonresponsiveness to the antigenic
peptide is the low level of transgenic T-cell receptor
on these cells.
Thymocyte Lines from F5/Thy-myc Mice
Unable to Rearrange Endogenous TCR
Receptors
In order to avoid the complications of endogenous
T-cell receptors being expressed during thymic de-
velopment of F5/Thy-myc double-transgenic mice,
use was made of a mouse line that is unable to
rearrange endogenous T-cell-receptor genes. These
mice are deficient in the Recombination Activating
Gene 1 (RAG-l) (Spanopoulou et al., 1994). In
RAG-1-/- mice, thymocyte development is arrested
at the double-negative CD4-8- stage. However,s if
such mice are crossed to transgenic mice carrying an
already rearranged -chain transgene, they proceed
to the double-positive (CD4
/ CD8 /) stage (Mom-
baerts et al., 1992).
F5/Thy-myc mice in RAG-1 -/- background were
generated and these developed thymic tumors at 2
to 6 months of age. Thymic tumor cells were stained
with CD4-, CD8-, V11-(transgenic), and HSA-
specific antibodies, analyzed on a fluorescence-
activated sorter, and the results are shown in Table
TABLE
FACScan Anaysis on Tumors in F5/TM/RAG-/- Mice
Mouse Age Thymus Metastasis
(weeks) V11 HSA
FS/TM/RAG-/-.1 8 Int. Low +
F5/TM/RAG-/-.2 18 High Int. +
F5/TM/RAG-/-.3 22 High High
F5/TM/RAG-/-.4 26 Low Low +
F5/TM/RAG-/-.5 22 Low Int. +
F5/TM/RAG-7-.6 26 Low Low +
Thymic tumors, lymph nodes, and spleens stained for CD4, CDS, and V11.
Expression of V11 and HSA varies amongst the thymuses. Peripheral metastasis of
CD4 CD8 thymic tumor cells observed in lymph nodes, spleens, both.
1. Interesting, but without explanation at the mo-
ment, is the high incidence of metastasis to periph-
eral lymphoid organs of these mice as opposed to
F5/TM/RAG
/ / / mice. Cell lines were isolated
from these tumors and were analyzed for expression
of CD4, CD8, V11, and HSA. Such cells were also
unresponsive to antigenic stimulus and parallel
studies indicated that whereas fresh tumor cells
were expressing high levels of F5 TCR, the lines
showed low or undetectable levels (data not shown).
RAG-l-/-/Thy-l-myc Mice Do Not Develop
Thymic Tumors
As mentioned before, in order for Thy-l-myc thy-
mocytes to be transformed and immortalized, a
secondary event is necessary. It has been postulated
before that the secondary event probably occurs at
the double-positive stage. Thy-l-myc/RAG-1 -l-
mice offer a unique genetic combination that could
further resolve this question. Indeed, we examined
over 30 Thy-l-myc/RAG-1-/- mice at ages from 3
months to 1 year and none of them showed any
signs of tumors. In contrast, as described before,
most of the F5 //Thy-l-myc //RAG-l-/- mice de-
veloped thymic tumors. This observation proves
that in order for Thy-myc thymocytes to be trans-
formed, they have to proceed to the double-positive
stage in development.
There could be two reasons why Thy-l-myc/
RAG-l-/- mice do not develop tumors. It is possi-
ble that the secondary event that cooperates with
the myc transgene for transformation occurs at the
double-positive stage. Alternatively, it is possible
that the myc transgene is not expressed in the
double-negative stage at levels that can transform
the thymocytes. In order to assess the latter possi-
bility, RAG-1-/- and RAG-1 +// thymocytes were
stained with Thy-1 antibodies. Figure 5 shows that
in RAG-l-/- mice, the double-negative CD4-8-
thymocytes express Thy-1 at high levels. This indi-
cates that the Thy-1 promoter is active in these cells,
excluding the possibility of transcriptional inactivity
of the Thy-myc transgene.
DISCUSSION
Immature T-cell lines were established from thymic
tumors in mice transgenic for Thy-1/c-myc and F5
TCR. The 25.1.2 cells express CD4 and CD8 at high
levels and are immature as judged by high-levelIMMATURE THYMOCYTE CELL LINES 285
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FIGURE 4. Response of 25.1.2 cells to steroid, peptide, and CD3 cross-linking treatment. (a) DNA fragmentation induced in 25.1.2
cells by steroids. (b) Survival of 25.1.2 cells (closed circles) and adult F5 thymocytes (open circles) after culture with different
concentrations of 1968 nucleoprotein peptide. Whereas the 1968 NP caused deletion of F5 thymocytes at 10
.9 M concentration, it did
not affect 25.1.2 cells even at the highest concentration. Cross-linking of CD3 on 25.1.2 cells by antibody (2Cll) bound to Fc receptors
on macrophage cell line J774A.1. The anti-CD3 antibody caused deletion of (c) 25.1.2 cells by programmed cell death as shown by
characteristic (d) DNA ladders at concentrations of 70 ng/ml or 10 lg/ml.286 M. MURDJEVA et al.
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FIGURE 5. Thy-l.2 expression on RAG-1 deficient and normal
(10) thymocytes. (a and b) Histograms show the staining of
RAG-1-/- and B10 thymocytes with anti-Thy-l.2 mAb.
HSA and their ability to undergo programmed cell
death upon induction with steroids. In contrast to
steroid treatment, however, 25.1.2 cells did not
respond to cognate peptide. This could be due to
uncoupling of the TCR/CD3 complex to signaling
pathways within the cell. To test this possibility,
CD3 was cross-linked on those cells; this led to
marked apoptosis, indicating that the CD3 complex
is linked functionally to signal-transduction mole-
cules. Therefore, the inability to induce apoptosis in
these cells with antigenic peptide is probably due to
insufficient levels of expression of the F5 TCR on
their surface. Alternatively, these cells may repre-
sent that population of immature thymocytes that
are resistant to negative selection through TCR
cross-linking, because not all of their TCR molecules
are coupled to the CD3 complex (Finkel et al., 1989).
Thus, signaling through CD3 would be efficient in
such cells and lead to apoptosis, whereas engaging
the T-cell receptor might be less effective.
25.1.2 cells transcribed both transgenic z and
chains, but also contained mRNA for rearranged
endogenous c and chain genes. It is generally
accepted that allelic exclusion of TCR genes is
strict and introduction of rearranged TCR [ genes in
transgenic mice prohibits thymocytes from rear-
ranging their endogenous TCR genes. The fact
that mRNA for endogenous rearranged TCR genes
was found in the 25.1.2 cells could be due to allelic
inclusion in F5 TCR transgenic mice. In fact, the
CD4 cells developing in these mice are selected
exclusively on endogenous receptor chains (z and or
) (Corbella et al., 1994). Alternatively, it is possible
that immortalized thymocytes continue to rearrange
TCR genes (Malissen et al., 1992).
Allelic exclusion of TCR {z genes, on the other
hand, is less strict and expression of dual TCR z
chains has been demonstrated in normal T cells
(Padovan et al., 1993). Our data on expression of
rearranged endogenous TCR genes in the F5 TCR
transgenic 25.1.2 cell line support the hypothesis
that this line is able to express, at the RNA level,
two T-cell receptors. CD3 levels on these cells also
suggest that possibly both receptors are expressed
on the surface.
In order to exclude the complications arising from
allelic inclusion or continuous rearrangement, we
crossed the F5/Thy-myc mice to mice deficient for
the RAG-1 gene. F5/Thy-myc/RAG-1-/- mice de-
veloped thymic tumors, thus excluding the possibil-
ity that endogenous receptor expression (and
signaling) was necessary for transformation of thy-
mocytes. The tumors themselves from both F5/
TM/RAG / and F5/TM/RAG-/- mice contained
cells that expressed the transgenic F5 chain at
appreciable levels. However, when placed in cul-
ture, these cells would gradually downregulate the
expression of the transgenic receptor in a course of
6 months. It is not clear at the moment why this
occurs. One possibility is that they lose copies of the
transgene. Nevertheless, transgenic mRNA could
still be detected making this an unlikely explanation.
An interesting point that arose from breeding the
Thy-myc transgene into the RAG-l-/- background
was that TM/RAG-1 -/- mice did not developIMMATURE THYMOCYTE CELL LINES 287
thymic tumors. Given that RAG-l-/- thymocytes
do not differentiate past the double-negative stage,
this finding supports our earlier hypothesis that
transformation of thymocytes in Thy-myc mice is a
rare event and needs, in addition to the myc gene, a
secondary event that occurs at the double-positive
stage.
MATERIALS AND METHODS
Mice
The Thy-1/c-myc (Spanopoulou et al., 1989) and F5
TCR (Mamalaki et al., 1992) transgenic mice were
generated in our laboratory. RAG-1 deficient mice
were generous gift by Eugenia Spanopoulou (Spa-
nopoulou et al., 1994). All mice including the
C57BL/10 (B10) strain were maintained in colonies
at the institute.
Flow Cytometry
Thymic tumor cells and cell lines were stained with
antibodies against CD4 (phycoerythrin-conjugated,
Boehringer-Mannheim), CD8 (fluorescein isothio-
cyanate-conjugated YTS169.4, ATCC), V11 (bioti-
nylated KT11, a gift from Dr. Tomonari), CD3a
(biotinylated 2Cl1-145, ATCC), heat-stable antigen
(biotinylated M1/114, ATCC), Thy-l.2 (biotinylated
HO13.4, ATCC), and streptavidin-tricolor
(CALTAG, California) or streptavidin phycoerythrin
(Biogenesis). Samples were analyzed on FACScan
(Becton Dickinson) using Lysis II Software (Becton
Dickinson).
Tissue Culture
Thymic tumors were mechanically disrupted and
thymocytes were cultured in 12 well plates (Nunc)
containing RPMI 1640 (Gibco) supplemented with
10% (v/v) heat-inactivated fetal calf serum
(Globepharm), 0.06 g/1 Penicillin, 0.1 g/1 Strepto-
mycin and 10 mM N-2 hydroxyethylpiperazine-N’-
2 ethanesulfonic acid. Cells were incubated at 37C
in a humidified chamber containing 5% CO2. Sub-
sequently, a clone designated F5.TM25.1.2 (abbre-
viated 25.1.2) was obtained by limiting dilution at
0.5 cell/well.
For analysis of programmed cell death, 25.1.2
cells were treated with 1 x 10
-6 M hydrocortisone
(Sigma) for 12 hr. Total DNA was extracted from
25.1.2 cells and was run in 2% agarose gel contain-
ing ethidium bromide as described before (Kawabe
and Ochi, 1992).
Peritoneal macrophages from B10 mice were pre-
pared according to Morikawa et al., 1993). Briefly,
the mouse peritoneal cavity was washed twice with
cold PBS, and adherent cells were collected after
incubation for 2 hr at 37C. Adherent cells were
further treated with 100 IU/ml murine recombinant
IFN-, for 12 hr, and were incubated with different
concentrations of 1968 NP peptide (366-374) (syn-
thesized at the National Institute for Medical Re-
search (London) for 90 min prior to coculture with
25.1.2 cells. 2 x 105 peritoneal macrophages were
cocultured with 5 x 105 25.1.2 cells for 12 hr. Lym-
phoid cells were recovered by gentle pipetting,
viable cell numbers were counted using trypan blue
dye exclusion, and cells were stained for CD4, CD8,
and V11. As a control, thymocytes from adult F5
transgenic mice were cocultured with macrophages
as before.
A murine macrophage cell line J774A.1 (TIB 67,
ATCC) was kindly provided by Dr. G. Stockinger
(NIMR). 25.1.2 cells were cocultured with J774A.1
in the presence or absence of anti-CD3 antibody
(2Cl1.145) at 0.07 or 10 tg/ml. After culture for 12
hr, fragmentation of DNA in 25.1.2 cells was ana-
lyzed as described before. In a separate experiment,
25.1.2 cells and F5 thymocytes were treated with
various concentrations of anti-CD3 antibody, and
cell numbers and expression of CD4, CD8, and
V11 were analyzed.
RNA-PCR Analysis
Total RNA was extracted from 25.1.2 cells by the
guanidinium thiocyanate method (Sambrook et al.,
1989), and was reverse-transcribed (RT) by Moloney
murine leukemia virus reverse transcriptase
(Promega) using oligo(dT) primers (Promega). One-
sixth of the RT products was amplified by poly-
merase chain reaction (PCR) in 1.5 mM MgC12, 60
mM KC1, 15 mM Tris-HC1 (pH 8.3), 6.75% glycerol,
and 2U Taq polymerase (Perkin Elmer) using ther-
mal cycler (Hybaid). Sense primers for TCR Vc and
V gene segments and an antisense primer for TCR
c constant region have been described before
(Casanova et al., 1991). In addition, the following
primers specific for transgenic F5 TCR were synthe-
sized in our institute, V(4: ACCAGAcAAGCT-
TCACCTGCcAAGATAT; V(4’: CAGTATCCCGG
AGAAGGTC; VI 1: CAAGCTCcTATAGAT-288 M. MURDJEVA et al.
GATTC; hCD2: TCAAAATCAGAAGGAAGCTGG;
and c: CCTTGGGTGGAGTCACATTTC. PCR re-
actions were also performed without cDNA as mock
controls. The PCR products were analyzed in 2%
agarose gels containing ethidium bromide. A molec-
ular size marker consisting of multimers of 123 bp
DNA fragments (Pharmacia) was used.
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